• Chengxi Han, Shuo Liu, Yunfeng Ji, Yuhua Hu, and Jingwen Zhang.
• Department of Neurosurgery, The Second Hospital of Hebei Medical University, Hebei, China.
• Medicine (Baltimore). 2024 May 10; 103 (19): e38066e38066.

AbstractCDCA3, a cell cycle regulator gene that plays a catalytic role in many tumors, was initially identified as a regulator of cell cycle progression, specifically facilitating the transition from the G2 phase to mitosis. However, its role in glioma remains unknown. In this study, bioinformatics analyses (TCGA, CGGA, Rembrandt) shed light on the upregulation and prognostic value of CDCA3 in gliomas. It can also be included in a column chart as a parameter predicting 3- and 5-year survival risk (C index = 0.86). According to Gene Set Enrichment Analysis and gene ontology analysis, the biological processes of CDCA3 are mainly concentrated in the biological activities related to cell cycle such as DNA replication and nuclear division. CDCA3 is closely associated with many classic glioma biomarkers (CDK4, CDK6), and inhibitors of CDK4 and CDK6 have been shown to be effective in tumor therapy. We have demonstrated that high expression of CDCA3 indicates a higher malignancy and poorer prognosis in gliomas.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

21 keywords...

hide…